<DOC>
	<DOC>NCT00907738</DOC>
	<brief_summary>This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.</brief_summary>
	<brief_title>A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Patient participated in one of the five vorinostat base protocols, has not shown tumor progression on that study, and has tolerated the study drug Patient did not withdraw from the base protocol Patient agrees to practice effective birth control during the study Patient is receiving other standard and/or investigational anticancer therapy Patient has any condition or disease that would interfere with compliance or pose addition risk in administering the study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>